

**ASAP: Antipsychotics for Members 18 Years of Age and Older**

**Member Information**

1. Last Name: \_\_\_\_\_ 2. First Name: \_\_\_\_\_  
3. Trillium ID #: \_\_\_\_\_ 4. Date of Birth: \_\_\_\_\_ 5. Gender: \_\_\_\_\_

**Prescriber Information**

1. Prescriber Name: \_\_\_\_\_ 2. NPI #: \_\_\_\_\_  
3. Requestor Name (Nurse/Office Staff): \_\_\_\_\_  
4. Mailing Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
5. Phone #: \_\_\_\_\_ Ext. \_\_\_\_\_ Fax #: \_\_\_\_\_

**Drug Information**

1. Drug Name: \_\_\_\_\_ 2. Strength: \_\_\_\_\_ 3. Quantity per 30 Days: \_\_\_\_\_  
4. Length of Therapy (in days): ☒ 365 Days

**Clinical Information**

**For Non-Preferred Medications:**

1. ☐ Failed 1 preferred drug? ☐ Yes ☐ No  
List preferred drugs failed: \_\_\_\_\_  
a. Was the failure due to an allergic reaction? ☐ Yes ☐ No  
b. Was the failure due to a drug-to-drug interaction? ☐ Yes ☐ No  
Please describe reaction: \_\_\_\_\_
2. ☐ Previous episode of an unacceptable side effect or therapeutic failure.  
Please provide clinical information: \_\_\_\_\_
3. ☐ Clinical contraindication, co-morbidity, or unique patient circumstance as a contraindication to preferred drug(s).  
Please provide clinical information: \_\_\_\_\_
4. ☐ Age specific indications. Please give patient age and explain: \_\_\_\_\_
5. ☐ Unique clinical indication supported by FDA approval or peer reviewed literature. Please explain and provide a general reference: \_\_\_\_\_
6. ☐ Unacceptable clinical risk associated with therapeutic change. Please explain: \_\_\_\_\_

**Criteria for All medications:**

7. What is the beneficiary's Primary Psychiatric diagnosis? ☐ Attention Deficit-Hyperactivity Disorder  
☐ Bipolar Disorder ☐ Disruptive Behavior Disorder ☐ Mood Disorder-NOS ☐ Any Pervasive Development Disorder  
☐ PTSD ☐ Schizophrenia ☐ Schizoaffective Disorder ☐ Tourette's Syndrome ☐ Other: \_\_\_\_\_
8. What is the beneficiary's target symptom? ☐ Aggression ☐ Impulsivity ☐ Inattentiveness ☐ Irritability ☐ Mania  
☐ Oppositional ☐ Psychosis ☐ Other: \_\_\_\_\_
9. Has the patient and/or guardian been informed of the potential metabolic adverse effects with this medication and wishes to continue to receive this therapy? ☐ Yes ☐ No
10. Has the patient and/or guardian been informed of the potential neurologic adverse effects with this medication and wishes to continue to receive this therapy? ☐ Yes ☐ No

Signature of Prescriber: \_\_\_\_\_ Date: \_\_\_\_\_

**(Prescriber Signature Mandatory)**

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.